ElBadawy, A., ElSayed, M., Abdullatif, I., AbdelMoneim, R. (2021). Impact of Hepatitis C virus Infection and direct-acting Oral Antiviral Drugs on glycaemic state in Type 2 Diabetic Patients. Benha Medical Journal, 38(1), 185-195. doi: 10.21608/bmfj.2021.58139.1371
Ayman ElBadawy; Mohamed ElSayed; Islam Abdullatif; Rasha AbdelMoneim. "Impact of Hepatitis C virus Infection and direct-acting Oral Antiviral Drugs on glycaemic state in Type 2 Diabetic Patients". Benha Medical Journal, 38, 1, 2021, 185-195. doi: 10.21608/bmfj.2021.58139.1371
ElBadawy, A., ElSayed, M., Abdullatif, I., AbdelMoneim, R. (2021). 'Impact of Hepatitis C virus Infection and direct-acting Oral Antiviral Drugs on glycaemic state in Type 2 Diabetic Patients', Benha Medical Journal, 38(1), pp. 185-195. doi: 10.21608/bmfj.2021.58139.1371
ElBadawy, A., ElSayed, M., Abdullatif, I., AbdelMoneim, R. Impact of Hepatitis C virus Infection and direct-acting Oral Antiviral Drugs on glycaemic state in Type 2 Diabetic Patients. Benha Medical Journal, 2021; 38(1): 185-195. doi: 10.21608/bmfj.2021.58139.1371
Impact of Hepatitis C virus Infection and direct-acting Oral Antiviral Drugs on glycaemic state in Type 2 Diabetic Patients
1Internal Medicine Faculty of Medicine, Banha University
2Professor Professor of Internal Medicine Head of Internal Medicine Department and Endocrinology unit Faculty of Medicine, Banha University
3MBBCH
Abstract
Background: Diabetes mellitus (DM) is strongly associated with chronic hepatitis C virus (HCV) infection. This work aimed to estimate the impact of Hepatitis C virus infection on glycaemic state and insulin resistance in type 2 Diabetic patients, and evaluate the effect of direct-acting oral antiviral treatment on the glycaemic state and insulin resistance in type 2 Diabetic patients. Methods: The study was performed on (40 patients) with Type 2 Diabetes who were infected by Hepatitis C Virus and took Direct-acting Oral Antiviral Drugs. The study also included (10 patients) who had Type 2 Diabetes and HCV infection serving as control group. All patients and control were subjected to thorough history taking, clinical examination, and lab. investigations as FBG, PP and HBA1c , Serum fasting Insulin level, And HOMA-IR, HCVab – HBsAg – HIVab, CBC, SGOT, SGPT, Serum Albumin and Bilirubin, PCR for HCV RNA, and Abdominal US. Results: DAAs-based eradication of HCV is associated with improved glycemic control in patients with type 2 diabetes as evidenced by a significant reduction of mean FBG, Fasting insulin, HbA1c, and HOMA IR. There was a positive correlation between the treatment of HCV infection and the reduction of anti-diabetic drugs used in the studied patients. Conclusion: DAAs-based eradication of HCV is associated with improved glycemic control in patients with type 2 diabetes.